Similar articles

• Leukocyte-reduced blood components in transfusion medicine. Current indications and prospects for the future.

  Klapper EB, Goldfinger D. Klapper EB, et al. Clin Lab Med. 1992 Dec;12(4):711-21. Clin Lab Med. 1992. PMID: 1286560 Review.
• The use of leukocyte-reduced blood components.

  Miller JP, Mintz PD. Miller JP, et al. Hematol Oncol Clin North Am. 1995 Feb;9(1):69-90. Hematol Oncol Clin North Am. 1995. PMID: 7737945 Review.
• Prestorage leukocyte depletion of blood products in a closed system.

  Pietersz RN, Steneker I, Reesink HW. Pietersz RN, et al. Transfus Med Rev. 1993 Jan;7(1):17-24. doi: 10.1016/s0887-7963(93)70029-2. Transfus Med Rev. 1993. PMID: 8431656 Review. No abstract available.
• Guidelines on the clinical use of leucocyte-depleted blood components. British Committee for Standards in Haematology, Blood Transfusion Task Force.

  [No authors listed] [No authors listed] Transfus Med. 1998 Mar;8(1):59-71. Transfus Med. 1998. PMID: 9569462 No abstract available.
• Clinical and laboratory precautions that reduce the adverse reactions, alloimmunization, infectivity, and possibly immunomodulation associated with homologous transfusions.

  Wenz B. Wenz B. Transfus Med Rev. 1990 Oct;4(4 Suppl 1):3-7. doi: 10.1016/s0887-7963(90)70236-2. Transfus Med Rev. 1990. PMID: 1966885 Review. No abstract available.